Ghent (Belgium), 2 April 2024, 6:00 a.m.; bonyf NV (Mnemonic: MLBON), the next-generation oral comfort expert, is a Euronext Paris listed company and specializes in the development, production and marketing of oral, denture, orthodontic and wound care products, is thrilled to announce the progression to Phase 2 in the development of its revolutionary Alginate-Organic Denture Fixative Cream.
Ghent (Belgium), 13 February 2024, 6:00 a.m.; bonyf NV (Mnemonic: MLBON), the next-generation oral comfort expert, is a Euronext Paris listed company and specializes in the development, production and marketing of oral, denture, orthodontic and wound care products, welcomes you to invest in its shares.
Ghent (Belgium), 11 January 2024, 6:00 a.m.; bonyf NV (Mnemonic: MLBON), the next-generation oral comfort expert, is thrilled to share that bonyf has secured key partnerships with an Austria-German multinational and a leading pharma company in Ukraine.
Ghent (Belgium), 22 December 2023, 6:00 a.m.; bonyf NV (Mnemonic: MLBON), the next-generation oral comfort expert, had asked for its shares to be suspended from trading following interest from a strategic investor in acquiring a 30% stake.
Ghent (Belgium), 20 July 2023, 6:00 p.m.; bonyf NV (Mnemonic: MLBON), the next-generation oral comfort expert, presents its 2022 consolidated financial statements, approved by its Board of Directors and audited by its Statutory Auditors
Ghent (Belgium), 30 June 2023; bonyf NV (Mnemonic: MLBON), a leading manufacturer of oral and denture care products announces its delay in the preparation and audit of the financial statements for the 2022 financial year.
VADUZ, Liechtenstein, 12 May 2023 – bonyf, a leading manufacturer of oral and denture care products is excited to announce its participation in the Private Label Manufacturers Association's (PLMA) annual trade show in Amsterdam.
Ghent (Belgium), 24 February 2023, 6:00 p.m.; bonyf NV (Mnemonic: MLBON), the next-generation oral comfort expert, announces the suspension of the listing of its shares at the request of the company.
VADUZ, Liechtenstein, 13 February 2023 – To comply with new stringent regulations enforced in Taiwan for the sale of medical device products, bonyf has received the TFDA (Taiwan Food and Drug Administration) approval for 2 core products.
GHENT, Belgium, 21 December 2022 – bonyf NV releases to its new shareholders the inaugural shareholder newsletter. The shareholder newsletter has been released by bonyf’s CEO and Founder, Mr Jean-Pierre Bogaert.
